CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
Conditions: Locally Advanced Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8; Unresectable Malignant Solid Neoplasm Interventions: Biological: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949; Drug: VLP-encapsulated TLR9 Agonist CMP-001 Sponsors: University of Southern California; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Melanoma | Pancreas | Pancreatic Cancer | Research | Skin Cancer